The invention relates to a liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and optionally at least one pharmaceutically acceptable adjuvant. The liquid composition is characterised in that it contains methionine optionally as add-on therapy with metformin and/or long-acting insulins/insulin derivatives.

A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof and (b) metformin or/and a pharmaceutically acceptable salt thereof  to a subject in need thereof.

A process for obtaining alphaalpha-dimethylphenylacetic acid wherein alphaalphadimethylbenzyl cyanide is reacted in the presence of sodium hydroxide water and a C4- and/or C5-alcohol at temperatures above about 100° C. and the alphaalpha-dimethylphenylacetic acid is obtained by acidification.

The present invention relates to acylated indanyl amines according to the general formula (I) wherein R1-R4 have the meanings given in the description A is CH2 CHOH or CH-(C1-C3-alkyl) B is CH2 or CH-(C1-C3-alkyl) and R5 is an aryl or heteroaryl group possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS) and may therefore be useful for the manufacture of medicaments for the treatment of cardi...

Crystal modification 2 of N-(4-trifluoromethylphenyl)-5-met hylisoxazole-4-carboxamide (I) (leflunomid; HWA 486) is new. - New crystal modification 2 of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide (I) has lines (diffraction angles 2theta ([deg])) of strong intensity at 10.65 14.20 14.80 16.10 21.70 23.15 24.40 24.85 25.50 25.85 26.90 and 29.85 and of medium intensity at 7.40 9.80 13.10 15.45 16.80 20.70 21.45 22.80 23.85 27.25 and 28.95 in the X-ray diffraction graph using Cu-Kal...

The present invention relates to use of an angiotensin II type 1 receptor (ATII) antagonist or a pharmaceutically acceptable salt thereof particularly candesartan or candesartan cilexetil in the manufacture of a medicament for the prevention of stroke diabetes and/or congestive heart failure (CHF).

The present invention is directed to solid stable pharmaceutical fixed dose compositions comprising ramipril amlodipine besilate and pharmaceutically acceptable excipients and to their preparation.

THE PRESENT INVENTION RELATES TO ACYLATED INDANYL AMINES ACCORDING TO THE GENERAL FORMULA (I) WHEREIN R?-R? HAVE THE MEANINGS GIVEN IN THE DESCRIPTION A IS CH? CHOH OR CH-(C?-C?-ALKYL)B IS CH? OR CH-(C?-C?-ALKYL) AND R? IS AN ARYL OR HETEROARYL GROUP POSSIBLY SUBSTITUTED BY THE SUBSTITUENTS LISTED IN THE DESCRIPTION. THESE COMPOUNDS ARE USEFUL IN THE UPREGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE (ENOS) AND MAY THEREFORE BE USEFUL FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF CARDI...